Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL

Edmund Waller • 23 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Pembrolizumab Tisagenlecleucel
JULIET Portia

Edmund Waller, MD, PhD, FACP, of the Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, discusses the safety and efficacy results of the PORTIA study (NCT03630159), a Phase Ib trial of tisagenlecleucel and pembrolizumab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Edmund Waller

Managing GvHD in patients undergoing SCT
1:12
Managing GvHD in patients undergoing SCT
Edmund Waller • 8 Sep 2023
Optimizing conditioning regimens in patients with AML undergoing alloSCT
1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
2:09
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
Edmund Waller • 8 Sep 2023
Duvelisib in CAR T-cell therapy for CLL
4:18
Duvelisib in CAR T-cell therapy for CLL
Edmund Waller • 1 Sep 2020

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Edmund Waller • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Edmund Waller • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Edmund Waller • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Edmund Waller • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals